Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer

Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil–based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to folfiri and f...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaulin, J., Kotb, R., Turcotte, E., Berard, G., Sawan, B., Schmutz, G., Beauregard, P.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768516/
https://www.ncbi.nlm.nih.gov/pubmed/19862366
_version_ 1782173476953522176
author Gaulin, J.
Kotb, R.
Turcotte, E.
Berard, G.
Sawan, B.
Schmutz, G.
Beauregard, P.
author_facet Gaulin, J.
Kotb, R.
Turcotte, E.
Berard, G.
Sawan, B.
Schmutz, G.
Beauregard, P.
author_sort Gaulin, J.
collection PubMed
description Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil–based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to folfiri and folfox chemotherapy regimens who showed a dramatic and durable response to bevacizumab and folfiri. We also review and discuss the available literature.
format Text
id pubmed-2768516
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Multimed Inc.
record_format MEDLINE/PubMed
spelling pubmed-27685162009-10-27 Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer Gaulin, J. Kotb, R. Turcotte, E. Berard, G. Sawan, B. Schmutz, G. Beauregard, P. Curr Oncol Case Report Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil–based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to folfiri and folfox chemotherapy regimens who showed a dramatic and durable response to bevacizumab and folfiri. We also review and discuss the available literature. Multimed Inc. 2009-09 /pmc/articles/PMC2768516/ /pubmed/19862366 Text en 2009 Multimed Inc. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Gaulin, J.
Kotb, R.
Turcotte, E.
Berard, G.
Sawan, B.
Schmutz, G.
Beauregard, P.
Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
title Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
title_full Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
title_fullStr Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
title_full_unstemmed Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
title_short Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
title_sort efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768516/
https://www.ncbi.nlm.nih.gov/pubmed/19862366
work_keys_str_mv AT gaulinj efficacyofthirdlinetherapyusingbevacizumabinapatientwithmetastaticcolorectalcancer
AT kotbr efficacyofthirdlinetherapyusingbevacizumabinapatientwithmetastaticcolorectalcancer
AT turcottee efficacyofthirdlinetherapyusingbevacizumabinapatientwithmetastaticcolorectalcancer
AT berardg efficacyofthirdlinetherapyusingbevacizumabinapatientwithmetastaticcolorectalcancer
AT sawanb efficacyofthirdlinetherapyusingbevacizumabinapatientwithmetastaticcolorectalcancer
AT schmutzg efficacyofthirdlinetherapyusingbevacizumabinapatientwithmetastaticcolorectalcancer
AT beauregardp efficacyofthirdlinetherapyusingbevacizumabinapatientwithmetastaticcolorectalcancer

Ejemplares similares